Alamar Biosciences, Inc. Common Stock ALMR

Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

• GlobeNewswire Inc. 24 sept

  Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

  A longitudinal study published in The Lancet Neurology using Alamar Biosciences' NULISAseq CNS 120 panel found that patients receiving lecanemab for early symptomatic Alzheimer's disease show markedly different biological responses. The research revealed that biomarkers associated with amyloid clearance differ from those associated with cognitive decline, explaining why clearing amyloid doesn't produce uniform clinical benefits across patients. The study measured 130 plasma proteins across 2,385 samples from 1,967 participants.

  

• GlobeNewswire Inc. 13 jul

  Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究

  Alamar Biosciences announced a national-scale proteomics initiative in collaboration with Washington University, University of Wisconsin, and Indiana University to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq Neuro 220 multiplex panel. The resulting open-access dataset will be linked to the National Alzheimer's Coordinating Center and will support AI-driven biomarker discovery and validation for neurodegenerative diseases.

  

• GlobeNewswire Inc. 13 jul

  Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究

  Alamar Biosciences announced a national research initiative in collaboration with top universities to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq™ Neuro 220 detection kit. The resulting dataset will be made publicly available through the National Alzheimer's Coordinating Center to support AI-driven research and accelerate biomarker discovery for neurodegenerative diseases.

  

• GlobeNewswire Inc. 13 jul

  Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

  Alamar Biosciences announced a partnership with leading research universities to launch a national-scale proteomics initiative profiling approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias participants using its NULISAseq Neuro 220 panel. The resulting dataset will be publicly accessible and open to AI-driven discovery through a national data challenge, advancing biomarker discovery for neurodegenerative diseases.

  

• GlobeNewswire Inc. 10 jul

  Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相，突顯基於血液的阿茲海默症生物標記剖析之最新進展

  Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) in London. The company highlighted advances in blood-based biomarker profiling, particularly the eMTBR-Tau and BD-pTau217 tests, which can be measured simultaneously with 220+ CNS-related proteins in a single workflow. This represents a four-fold increase from the previous AAIC conference, demonstrating growing adoption of the technology in Alzheimer's research.